SYN007 contains long acting anti-muscarinic agent Tiotropium as active ingredient. The indication is chronic pulmonary obstructive disease (COPD). It is considered as a new dosage form for replacing the dry powder inhaler (DPI) product SPIRIVA, which is expected to relieve cardiovascular side effects through the adjustment of the particle size of the drug. It would be submitted under US. FD&C Act 505(b)(2).